Hennion & Walsh Asset Management’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
CFM
ORI
BC
DT
PFSRSONJ
CUAMC
HCMT
YMRC
Hennion & Walsh Asset Management's TVTX Position: Q2 2026 in Review
Hennion & Walsh Asset Management increased its Travere Therapeutics (TVTX) stake by 51% in Q2 2026, buying an estimated $2.57M and bringing the position to 171,470 shares worth $9.74M. The position accounts for 0.28% of the portfolio, ranked #74.
Hennion & Walsh Asset Management first reported a position in TVTX in Q4 2021 and has held it in 17 quarters since. 35 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- Hennion & Walsh Asset Management held 171,470 shares of Travere Therapeutics worth $9.74M as of Q2 2026.
- Hennion & Walsh Asset Management bought 57,959 Travere Therapeutics shares in Q2 2026, an estimated $2.57M.
- Travere Therapeutics made up 0.28% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #74 holding.
- Hennion & Walsh Asset Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 17 quarters since.
- 35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.